Ardelyx (ARDX) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of November 26, 2042. The patent relates to the formulation of tenapanor and covers the commercial formulations of Isbrela and Xphozah. The patent will be submitted to the Food and Drug Administration for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations for both products. Published first on T ...